Skip to main content
Photo of  Alok Sahay, MD

Alok Sahay, MD

Professor of Clinical-Affiliate

Neurology & Rehabilitation Medicine | College of Medicine

Education/Credentials
  • Fellowship: Oregon Health Sciences University (Movement Disorders)
  • Residency: University of Cincinnati (Neurology)
  • Residency: The Christ Hospital
  • Medical Degree: Sawai Man Singh Medical College
  • Resident : Sawai Man Singh Medical College
  • : Sawai Man Singh Medical College and Attached Hospitals
  • Bachelor's Degree: Sawai Man Singh Medical College
Board Certifications & Licenses

American Board of Psychiatry and Neurology (Neurology) (Certification Date: 2002-01-22) - (Recertification Date: 2012-02-27)

Specialties

Neurology

Contact Information

Clinical Interests

Movement Disorders

Neurology

Parkinson's Disease

Alzheimer's Disease

Ataxia

Balance Disorders

Bell's Palsy

Cataplexy

Catatonia

Cerebellar Ataxia

Chorea

Corticobasal Degeneration (CBD)

Dementia

Dyskinesias

Dystonia

Essential Tremor (ET)

Gait Disorders

Hemifacial Spasm

Hereditary Spastic Paraplegia

Huntington's Disease

Hyperkalemic Periodic Paralysis

Hypokalemic Periodic Paralysis

Lewy Body Dementia

Lewy Body Disease

Multiple System Atrophy (MSA)

Muscle Rigidity

Muscle Spasticity

Myoclonic Seizures

Normal Pressure Hydrocephalus

Orthostatic Hypotension (Postural Hypotension)

Paraparesis

Parkinson's Hypophonia (Bowing/Atrophy)

Posterior Cortical Atrophy

Prion Disease

Psychomotor Disorders

Sensory Ataxia

Serotonin Syndrome

Spasms

Spinocerebellar Ataxia (SCA)

Spinocerebellar Degenerations

Stiff-Person Syndrome

Subacute Combined Degeneration

Tauopathies

Tay-Sachs Disease

TDP-43 Proteinopathies

Tics and Tourette Syndrome

Tourette Syndrome

Tremors

Tropical Spastic Paraparesis

Vascular Cognitive Impairment

Vascular Dementia

Wernicke Encephalopathy

Peer Reviewed Publications

Beal,M. F., Oakes,D., Shoulson,I., Henchcliffe,C., Galpern,W. R., Haas,R., Juncos,J. L., Nutt,J. G., Voss,T. S., Ravina,B., Shults,C. M., Helles,K., Snively,V., Lew,M. F., Griebner,B., Watts,A., Gao,S., Pourcher,E., Bond,L., Kompoliti,K., Agarwal,P., Sia,C., Jog,M., Cole,L., Sultana,M., Kurlan,R., Richard,I., Deeley,C., Waters,C. H., Figueroa,A., Arkun,A., Brodsky,M., Ondo,W. G., Hunter,C. B., Jimenez-Shahed,J., Palao,A., Miyasaki,J. M., So,J., Tetrud,J., Reys,L., Smith,K., Singer,C., Blenke,A., Russell,D. S., Cotto,C., Friedman,J. H., Lannon,M., Zhang,L., Drasby,E., Kumar,R., Subramanian,T., Ford,D. S., Grimes,D. A., Cote,D., Conway,J., Siderowf,A. D., Evatt,M. L., Sommerfeld,B., Lieberman,A. N., Okun,M. S., Rodriguez,R. L., Merritt,S., Swartz,C. L., Martin,W. R., King,P., Stover,N., Guthrie,S., Watts,R. L., Ahmed,A., Fernandez,H. H., Winters,A., Mari,Z., Dawson,T. M., Dunlop,B., Feigin,A. S., Shannon,B., Nirenberg,M. J., Ogg,M., Ellias,S. A., Thomas,C. A., Frei,K., Bodis-Wollner,I., Glazman,S., Mayer,T., Hauser,R. A., Pahwa,R., Langhammer,A., Ranawaya,R., Derwent,L., Sethi,K. D., Farrow,B., Prakash,R., Litvan,I., Robinson,A., Sahay,A., Gartner,M., Hinson,V. K., Markind,S., Pelikan,M., Perlmutter,J. S., Hartlein,J., Molho,E., Evans,S., Adler,C. H., Duffy,A., Lind,M., Elmer,L., Davis,K., Spears,J., Wilson,S., Leehey,M. A., Hermanowicz,N., Niswonger,S., Shill,H. A., Obradov,S., Rajput,A., Cowper,M., Lessig,S., Song,D., Fontaine,D., Zadikoff,C., Williams,K., Blindauer,K. A., Bergholte,J., Propsom,C. S., Stacy,M. A., Field,J., Mihaila,D., Chilton,M., Uc,E. Y., Sieren,J., Simon,D. K., Kraics,L., Silver,A., Boyd,J. T., Hamill,R. W., Ingvoldstad,C., Young,J., Thomas,K., Kostyk,S. K., Wojcieszek,J., Pfeiffer,R. F., Panisset,M., Beland,M., Reich,S. G., Cines,M., Zappala,N., Rivest,J., Zweig,R., Lumina,L. P., Hilliard,C. L., Grill,S., Kellermann,M., Tuite,P., Rolandelli,S., Kang,U. J., Rao,J., Cook,M. M., Severt,L., Boyar,K., Investigators,Parkinson Study Group QE3 2014. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit JAMA Neurol, 71 5, 543

Hauser,R. A., Silver,D., Choudhry,A., Eyal,E., Isaacson,S., investigators,ANDANTE study 2014. Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson';s disease Mov Disord, 29 8, 1028

Marek,K., Seibyl,J., Eberly,S., Oakes,D., Shoulson,I., Lang,A. E., Hyson,C., Jennings,D., Investigators,Parkinson Study Group PRECEPT 2014. Longitudinal follow-up of SWEDD subjects in the PRECEPT Study Neurology, 82 20, 1791

Nalls,M. A., Pankratz,N., Lill,C. M., Do,C. B., Hernandez,D. G., Saad,M., DeStefano,A. L., Kara,E., Bras,J., Sharma,M., Schulte,C., Keller,M. F., Arepalli,S., Letson,C., Edsall,C., Stefansson,H., Liu,X., Pliner,H., Lee,J. H., Cheng,R., Ikram,M. A., Ioannidis,J. P., Hadjigeorgiou,G. M., Bis,J. C., Martinez,M., Perlmutter,J. S., Goate,A., Marder,K., Fiske,B., Sutherland,M., Xiromerisiou,G., Myers,R. H., Clark,L. N., Stefansson,K., Hardy,J. A., Heutink,P., Chen,H., Wood,N. W., Houlden,H., Payami,H., Brice,A., Scott,W. K., Gasser,T., Bertram,L., Eriksson,N., Foroud,T., Singleton,A. B., (IPDGC),International Parkinson's Disease Genomics Consortium, (PROGENI),Parkinson's Study Group (PSG) Parkinson's Research: The Organized GENetics Initiative, 23andMe, GenePD, (NGRC),NeuroGenetics Research Consortium, (HIHG),Hussman Institute of Human Genomics, Investigator,Ashkenazi Jewish Dataset, (CHARGE),Cohorts for Health and Aging Research in Genetic Epidemiology, (NABEC),North American Brain Expression Consortium, (UKBEC),United Kingdom Brain Expression Consortium, Consortium,Greek Parkinson's Disease, Group,Alzheimer Genetic Analysis 2014. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson';s disease Nat Genet, 46 9, 989

Stocchi,F., investigators,ADAGIO 2014. Benefits of treatment with rasagiline for fatigue symptoms in patients with early Parkinson';s disease Eur J Neurol, 21 2, 357

Evidente,V. G., Fernandez,H. H., LeDoux,M. S., Brashear,A., Grafe,S., Hanschmann,A., Comella,C. L. 2013. A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin(®)) in cervical dystonia J Neural Transm, 120 12, 1699

Fernandez,H. H., Pappert,E. J., Comella,C. L., Evidente,V. G., Truong,D. D., Verma,A., Jankovic,J. 2013. Efficacy and Safety of IncobotulinumtoxinA in Subjects Previously Treated with Botulinum Toxin Versus Toxin-Naïve Subjects with Cervical Dystonia Tremor Other Hyperkinet Mov (N Y), 3 ,

Group,Parkinson Study 2013. Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson';s disease (STEADY-PD) Mov Disord, 28 13, 1823

Truong,D. D., Gollomp,S. M., Jankovic,J., LeWitt,P. A., Marx,M., Hanschmann,A., Fernandez,H. H., Group,Xeomin US Blepharospasm Study 2013. Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin(®)) injections in blepharospasm J Neural Transm, 120 9, 1345

Pankratz,N., Beecham,G. W., DeStefano,A. L., Dawson,T. M., Doheny,K. F., Factor,S. A., Hamza,T. H., Hung,A. Y., Hyman,B. T., Ivinson,A. J., Krainc,D., Latourelle,J. C., Clark,L. N., Marder,K., Martin,E. R., Mayeux,R., Ross,O. A., Scherzer,C. R., Simon,D. K., Tanner,C., Vance,J. M., Wszolek,Z. K., Zabetian,C. P., Myers,R. H., Payami,H., Scott,W. K., Foroud,T., Consortium,PD GWAS 2012. Meta-analysis of Parkinson';s disease: identification of a novel locus, RIT2 Ann Neurol, 71 3, 370

Comella,C. L., Jankovic,J., Truong,D. D., Hanschmann,A., Grafe,S., Group,U. S. XEOMIN Cervical Dystonia Study 2011. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia J Neurol Sci, 308 1-2, 103

Espay,A. J., Dwivedi,A. K., Payne,M., Gaines,L., Vaughan,J. E., Maddux,B. N., Slevin,J. T., Gartner,M., Sahay,A., Revilla,F. J., Duker,A. P., Shukla,R. 2011. Methylphenidate for gait impairment in Parkinson disease A randomized clinical trial Neurology, 76 14, 1256

Espay,Alberto J., Giuffrida,Joe P., Chen,Robert, Payne,Megan, Mazzella,Filomena, Dunn,Emily, Vaughan,Jennifer E., Duker,Andrew P., Sahay,Alok, Kim,Sang Jin, Revilla,Fredy J., Heldman,Dustin A. 2011. Differential response of speed, amplitude, and rhythm to dopaminergic medications in Parkinson';s disease Movement Disorders, 26 14, 2504

Espay,Alberto J., Vaughan,Jennifer E., Shukla,Rakesh, Gartner,Maureen, Sahay,Alok, Revilla,Fredy J., Duker,Andrew P. 2011. Botulinum Toxin Type A for Levodopa-Induced Cervical Dyskinesias in Parkinson';s Disease: Unfavorable Risk-Benefit Ratio Movement Disorders, 26 5, 913

Heldman,Dustin A., Giuffrida,Joseph P., Chen,Robert, Payne,Megan, Mazzella,Filomena, Duker,Andrew P., Sahay,Alok, Kim,Sang Jin, Revilla,Fredy J., Espay,Alberto J. 2011. The Modified Bradykinesia Rating Scale for Parkinson';s Disease: Reliability and Comparison with Kinematic Measures Movement Disorders, 26 10, 1859

Kieburtz,Karl, Parkinson Study Grp Prami,B. I. D. 2011. Twice-Daily, Low-Dose Pramipexole in Early Parkinson';s Disease: A Randomized, Placebo-Controlled Trial Movement Disorders, 26 1, 37

Marras,Connie, McDermott,Michael P., Marek,Ken, Rochon,Paula, Naglie,Gary, Tanner,Caroline M., Rudolph,Alice, Shoulson,Ira, Lang,Anthony E., Parkinson Study Grp,Datatop Invest, Parkinson Study Grp,Precept Invest 2011. Predictors of Time to Requiring Dopaminergic Treatment in 2 Parkinson';s Disease Cohorts Movement Disorders, 26 4, 608

Pankratz,N., Dumitriu,A., Hetrick,K. N., Sun,M., Latourelle,J. C., Wilk,J. B., Halter,C., Doheny,K. F., Gusella,J. F., Nichols,W. C., Myers,R. H., Foroud,T., DeStefano,A. L., PSG-PROGENI and GenePD Investigators,C.ordinators and Molecular Genetic Laboratories 2011. Copy number variation in familial Parkinson disease PLoS One, 6 8, e20988

Schwarzschild,Michael A., Marek,Kenneth, Eberly,Shirley, Oakes,David, Shoulson,Ira, Jennings,Danna, Seibyl,John, Ascherio,Alberto, Parkinson Study Grp,Precept 2011. Serum Urate and Probability of Dopaminergic Deficit in Early "Parkinson';s Disease" Movement Disorders, 26 10, 1864

Schwid,Steven R., Bausch,Janice, Oakes,David, Schuchter,Lynn, Tanner,Caroline, Forrest,Misser, Lang,Anthony E., Shoulson,Ira, Investigators,Psg Precept 2010. Cancer Incidence in a Trial of an Antiapoptotic Agent for Parkinson';s Disease Movement Disorders, 25 12, 1801

Simon,David K., Pankratz,Nathan, Kissell,Diane K., Pauciulo,Michael W., Halter,Cheryl A., Rudolph,Alice, Pfeiffer,Ronald F., Nichols,William C., Foroud,Tatiana, Parkinson Study Grp,Progeni Invest 2010. Maternal inheritance and mitochondrial DNA variants in familial Parkinson';s disease Bmc Medical Genetics, 11 ,

Watts,R. L., Lyons,K. E., Pahwa,R., Sethi,K., Stern,M., Hauser,R. A., Olanow,W., Gray,A. M., Adams,B., Earl,N. L., Investigators,228 Study 2010. Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson';s disease Mov Disord, 25 7, 858

Latourelle,J. C., Pankratz,N., Dumitriu,A., Wilk,J. B., Goldwurm,S., Pezzoli,G., Mariani,C. B., DeStefano,A. L., Halter,C., Gusella,J. F., Nichols,W. C., Myers,R. H., Foroud,T., PROGENI Investigators,C.ordinators and Molecular Genetic Laboratories, GenePD Investigators,C.ordinators and Molecular Genetic Laboratories 2009. Genomewide association study for onset age in Parkinson disease BMC Med Genet, 10 , 98

Marras,Connie, Lang,Anthony E., Eberly,Shirley W., Oakes,David, Fahn,Stanley, Schwid,Steven R., Hyson,Christopher, Shoulson,Ira, Parkinson Study Grp,Datatop Precep 2009. A Comparison of Treatment Thresholds in Two Large Parkinson';s Disease Clinical Trial Cohorts Movement Disorders, 24 16, 2370

Nichols,W. C., Kissell,D. K., Pankratz,N., Pauciulo,M. W., Elsaesser,V. E., Clark,K. A., Halter,C. A., Rudolph,A., Wojcieszek,J., Pfeiffer,R. F., Foroud,T., Parkinson Study Grp,Progeni Invest 2009. Variation in GIGYF2 is not associated with Parkinson disease Neurology, 72 22, 1886

Nichols,W. C., Pankratz,N., Marek,D. K., Pauciulo,M. W., Elsaesser,V. E., Halter,C. A., Rudolph,A., Wojcieszek,J., Pfeiffer,R. F., Foroud,T., Parkinson Study Grp,Progeni 2009. Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset Neurology, 72 4, 310

Olanow,C. W., Rascol,O., Hauser,R., Feigin,P. D., Jankovic,J., Lang,A., Langston,W., Melamed,E., Poewe,W., Stocchi,F., Tolosa,E., Investigators,ADAGIO Study 2009. A double-blind, delayed-start trial of rasagiline in Parkinson';s disease N Engl J Med, 361 13, 1268

Pankratz,N., Kissell,D. K., Pauciulo,M. W., Halter,C. A., Rudolph,A., Pfeiffer,R. F., Marder,K. S., Foroud,T., Nichols,W. C., Parkinson Study Grp,Progeni Invest 2009. Parkin dosage mutations have greater pathogenicity in familial PD than simple sequence mutations Neurology, 73 4, 279

Pankratz,N., Wilk,J. B., Latourelle,J. C., DeStefano,A. L., Halter,C., Pugh,E. W., Doheny,K. F., Gusella,J. F., Nichols,W. C., Foroud,T., Myers,R. H., PSG-PROGENI and GenePD Investigators,C.ordinators and Molecular Genetic Laboratories 2009. Genomewide association study for susceptibility genes contributing to familial Parkinson disease Hum Genet, 124 6, 593

Pankratz,Nathan, Nichols,William C., Elsaesser,Veronika E., Pauciulo,Michael W., Marek,Diane K., Halter,Cheryl A., Wojcieszek,Joanne, Rudolph,Alice, Pfeiffer,Ronald F., Foroud,Tatiana, Parkinson Study Grp,Progeni Invest 2009. Alpha-Synuclein and Familial Parkinson';s Disease Movement Disorders, 24 8, 1125

Pankratz,N., Marder,K. S., Halter,C. A., Rudolph,A., Shults,C. W., Nichols,W. C., Foroud,T., Investigators,Parkinson's Study Group-PROGENI 2008. Clinical correlates of depressive symptoms in familial Parkinson';s disease Mov Disord, 23 15, 2216

Schwarzschild,M. A., Schwid,S. R., Marek,K., Watts,A., Lang,A. E., Oakes,D., Shoulson,I., Ascherio,A., Hyson,C., Gorbold,E., Rudolph,A., Kieburtz,K., Fahn,S., Gauger,L., Goetz,C., Seibyl,J., Forrest,M., Ondrasik,J., Investigators,Parkinson Study Group PRECEPT 2008. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease Arch Neurol, 65 6, 716

Goetz,C. G., Damier,P., Hicking,C., Laska,E., Müller,T., Olanow,C. W., Rascol,O., Russ,H. 2007. Sarizotan as a treatment for dyskinesias in Parkinson';s disease: a double-blind placebo-controlled trial Mov Disord, 22 2, 179

Investigators,Parkinson Study Group PRECEPT 2007. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease Neurology, 69 15, 1480

Nichols,W. C., Elsaesser,V. E., Pankratz,N., Pauciulo,M. W., Marek,D. K., Halter,C. A., Rudolph,A., Shults,C. W., Foroud,T., Parkinson Study Grp,Progeni Invest 2007. LRRK2 mutation analysis in Parkinson disease families with evidence of linkage to PARK8 Neurology, 69 18, 1737

Nichols,William C., Marek,Diane K., Pauciulo,Michael W., Pankratz,Nathan, Halter,Cheryl A., Rudolph,Alice, Shults,Clifford W., Wojcieszek,Joanne, Foroud,Tatiana, Investigators,Progeni 2007. R1514Q substitution in Lrrk2 is not a pathogenic Parkinson';s disease mutation Movement Disorders, 22 2, 254

Blindauer,K., Shoulson,I., Oakes,D., Kieburtz,K., Schwid,S., Fahn,S., Stern,M., Goetz,C., Nutt,J., Plumb,S., Shinaman,A., Truong,D., Pahwa,R., Factor,S., Evans,S., Wojcieszek,J., Belden,J., Adler,C., Lind,M., Panisset,M., Hall,J., Suchowersky,O., Derwent,L., Di Rocco,A., Boyar,K., Ondo,W., Hunter,C., Colcher,A., Aminoff,M., Dowling,G., Outlaw,H., Dalvi,A., Sahay,A., Schwieterman,D., Elmer,L., Weiner,W., Cines,M., Dignon,C., Frucht,S., Benabou,R., Rajput,A., Ewanishin,M., Jennings,D., Stavris,K., Martin,W., McInnes,G., King,P., Feigin,A., Shannon,B., Gordon,M. F., Atchison,P., Mendis,T., Mendis,N., Reich,S., Dunlop,B., Petzinger,G., Armstrong,C., Welsh,M., Pfeiffer,R., Pfeiffer,B., Tuite,P., Calabrese,V., Roberge,P., Jog,M., Horn,C., Blackstone,C., Growdon,J., Tennis,M., Hauser,R., Gauger,L., Stacy,M., Williamson,K., O'Brien,C., Seeberger,L., Judd,D., Demarcaida,A., Belber,S., Perlmutter,J., McGee-Minnich,L., Ramos,C. S., Berrios,L., Bertoni,J., Peterson,C., Marshall,F., Deeley,C., Verhagen,L., Jaglin,J., Koller,W., Lyons,K., Singer,C., Blenke,A., Mark,M., Caputo,D., Tarsy,D., Scollins,L., Thomas,C. A., Rivest,J., Soucy,D., Bausch,J., Brocht,A., Daigneault,S., Eberly,S., Irvine,C., Lindsay,P., Weaver,C., Tariot,P., Cox,C., Leventhal,C., Goren,S., Sayag,N., Scolnik,M., Levy,R., Eyal,E., Salzman,P., Pagano,M., Parkinson Study,Grp 2006. A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations Archives of Neurology, 63 2, 210

Pankratz,N., Pauciulo,M. W., Elsaesser,V. E., Marek,D. K., Halter,C. A., Rudolph,A., Shults,C. W., Foroud,T., Nichols,W. C., Investigators,Parkinson Study Group-PROGENI 2006. Mutations in LRRK2 other than G2019S are rare in a north American-based sample of familial Parkinson';s disease Mov Disord, 21 12, 2257

Pankratz,Nathan, Pauciulo,Michael W., Elsaesser,Veronika E., Marek,Diane K., Halter,Cheryl A., Wojcieszek,Joanne, Rudolph,Alice, Shults,Clifford W., Foroud,Tatiana, Nichols,William C., Parkinson Study Grp,Progeni Invest 2006. Mutations in DJ-1 are rare in familial Parkinson disease Neuroscience letters, 408 3, 209

Schmit,J. M., Riley,M. A., Dalvi,A., Sahay,A., Shear,P. K., Shockley,K. D., Pun,R. Y. 2006. Deterministic center of pressure patterns characterize postural instability in Parkinson';s disease Exp Brain Res, 168 3, 357

Strong,J. A., Dalvi,A., Revilla,F. J., Sahay,A., Samaha,F. J., Welge,J. A., Gong,J., Gartner,M., Yue,X., Yu,L. 2006. Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson';s disease Mov Disord, 21 5, 654

Yang,T., Lu,A. G., Ran,R. Q., Aronow,B. J., Schorry,E. K., Hopkin,R. J., Gilbert,D. L., Glauser,T. A., Hershey,A. D., Richtand,N. W., Privitera,M., Dalvi,A., Sahay,A., Szaflarski,J. P., Ficker,D. M., Ratner,N., Sharp,F. R. 2004. Human blood genomics: distinct profiles for gender, age and neurofibromatosis type 1 Molecular Brain Research, 132 2, 155